Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology
- PMID: 34482706
- PMCID: PMC8649542
- DOI: 10.1161/JAHA.121.021686
Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology
Erratum in
-
Correction to: Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology.J Am Heart Assoc. 2023 May 16;12(10):e027687. doi: 10.1161/JAHA.121.027687. Epub 2023 May 9. J Am Heart Assoc. 2023. PMID: 37158160 Free PMC article. No abstract available.
Abstract
Radiation therapy demonstrates a clear survival benefit in the treatment of several malignancies. However, cancer survivors can develop a wide array of cardiotoxic complications related to radiation. This pathology is often underrecognized by clinicians and there is little known on how to manage this population. Radiation causes fibrosis of all components of the heart and significantly increases the risk of coronary artery disease, cardiomyopathy, valvulopathy, arrhythmias, and pericardial disease. Physicians should treat other cardiovascular risk factors aggressively in this population and guidelines suggest obtaining regular imaging once symptomatology is established. Patients with radiation-induced cardiovascular disease tend to do worse than their traditional counterparts for the same interventions. However, there is a trend toward fewer complications and lower mortality with catheter-based rather than surgical approaches, likely because radiation makes these patients poor surgical candidates. When appropriate, these patients should be referred for percutaneous management of valvulopathy and coronary disease.
Keywords: cancer survivors; cardiomyopathies; cardiotoxicity; cardiovascular diseases; coronary artery disease; fibrosis; heart disease risk factors.
Conflict of interest statement
None.
Figures
References
-
- Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, Mavroidis P, Lee CB, Jensen BC, Rosenman JG, et al. Cardiac toxicity after radiotherapy for stage III non‐small‐cell lung cancer: pooled analysis of dose‐escalation trials delivering 70 to 90 Gy. J Clin Oncol. 2017;35:1387–1394. doi: 10.1200/JCO.2016.70.0229 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
